Study of Safety and Immunogenicity of BVRS-GamVac-Combi

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
The Middle East respiratory syndrome coronavirus (MERS-CoV) was identified in 2012 during the first Middle East respiratory syndrome (MERS) outbreak. MERS-CoV causes an acute lower-respiratory infection in humans, with a fatality rate of \~34.5%. The aim of the study is to assess the safety and immunogenicity of heterologous adenoviral-based vaccine against MERS - BVRS-GamVac-Combi.
Epistemonikos ID: 855aaebc688dc0fa16654ebe03f7e1f739a7ff6d
First added on: Mar 23, 2020